GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.87 $1.65 Thursday, 18th Apr 2024 ADAP stock ended at $0.90. This is 8.98% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 13.44% from a day low at $0.87 to a day high of $0.99.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
2021-08-10 $3.55 $3.87 $3.53 $3.57 1 413 748
2021-08-09 $3.47 $3.61 $3.45 $3.45 623 683
2021-08-06 $3.50 $3.54 $3.40 $3.49 417 213
2021-08-05 $3.46 $3.60 $3.41 $3.53 441 048
2021-08-04 $3.49 $3.53 $3.43 $3.44 362 457
2021-08-03 $3.58 $3.64 $3.45 $3.48 351 951
2021-08-02 $3.66 $3.66 $3.57 $3.58 250 700
2021-07-30 $3.57 $3.64 $3.51 $3.57 348 770
2021-07-29 $3.69 $3.75 $3.60 $3.61 260 681
2021-07-28 $3.55 $3.71 $3.55 $3.65 435 316
2021-07-27 $3.51 $3.58 $3.37 $3.54 715 529
2021-07-26 $3.59 $3.71 $3.51 $3.51 299 360
2021-07-23 $3.84 $3.92 $3.61 $3.62 443 673
2021-07-22 $3.98 $3.98 $3.75 $3.77 305 012
2021-07-21 $3.95 $3.98 $3.78 $3.97 1 236 998
2021-07-20 $3.67 $3.94 $3.65 $3.90 1 565 435
2021-07-19 $3.65 $3.72 $3.55 $3.69 625 706
2021-07-16 $3.79 $3.83 $3.65 $3.71 391 043
2021-07-15 $3.72 $3.76 $3.63 $3.74 604 301
2021-07-14 $3.88 $3.90 $3.70 $3.73 550 588
2021-07-13 $3.94 $3.95 $3.81 $3.87 422 740
2021-07-12 $4.13 $4.17 $3.93 $3.95 211 973
2021-07-09 $4.07 $4.11 $3.99 $4.10 193 540
2021-07-08 $3.89 $4.05 $3.87 $4.03 375 009
2021-07-07 $4.17 $4.17 $3.90 $4.01 566 111
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT